Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Intravitreal Ketorolac for Chronic Uveitis: A Investigational Safety Study (INCITE)

This study has been completed.
Information provided by (Responsible Party):
Stephen J. Kim, MD, Vanderbilt University Identifier:
First received: April 19, 2010
Last updated: December 30, 2013
Last verified: December 2013
Intraocular delivery of ketorolac will be an effective means to treat inflammation and macular edema and prevent structural complications and vision loss in patients with uveitis who are unable to tolerate corticosteroids due to their side effects.

Condition Intervention Phase
Drug: Intravitreal Ketorolac
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Intravitreal Ketorolac for Chronic Uveitis:A Phase I Investigational Safety Study

Resource links provided by NLM:

Further study details as provided by Vanderbilt University:

Primary Outcome Measures:
  • Safety [ Time Frame: 90 days ]
    Baseline and 90 day electroretinogram and goldmann visual fields will be compared to assess for retinal toxicity.

Enrollment: 10
Study Start Date: December 2009
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ketorolac
4mg intravitreal injection of ketorolac
Drug: Intravitreal Ketorolac
4mg of intravitreal ketorolac
Other Name: ketorolace, tromethamine, preservative free

Detailed Description:

A Phase I safety study of intravitreal ketorolac in patients with chronic inflammation and complications due to inflammation who have either failed medical therapy or who cannot tolerate corticosteroids due to side effects.

Specific Aims

  1. Test the safety of intraocular injection of 4mg of ketorolac in patients who have intractable uveitis or complications of uveitis such as chronic macular edema who are unable to tolerate corticosteroids due to their side effects.
  2. Test the efficacy of intraocular 4m ketorolac of treating inflammation or structural complications of inflammation in patients with uveitis who are unable to tolerate corticosteroids due to their side effects.

Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult volunteers
  • Chronic intractable uveitis or chronic complications of uveitis (macular edema)despite maximal medical treatment
  • Unable to tolerate corticosteroids due to side effects

Exclusion Criteria:

  • 18 years or younger
  • Have active ocular infection
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01164085

United States, Tennessee
Vanderbilt Eye Institute
Nashville, Tennessee, United States, 37232-8808
Sponsors and Collaborators
Vanderbilt University
Principal Investigator: Stephen J Kim, MD Vanderbilt University
  More Information

Additional Information:
Responsible Party: Stephen J. Kim, MD, Principal Investigator, Vanderbilt University Identifier: NCT01164085     History of Changes
Other Study ID Numbers: 091196
Study First Received: April 19, 2010
Last Updated: December 30, 2013

Keywords provided by Vanderbilt University:
Macular Edema

Additional relevant MeSH terms:
Pathologic Processes
Uveal Diseases
Eye Diseases
Ketorolac Tromethamine
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on April 28, 2017